Influenza Vaccine

The RNA-based strategy targets a part of the viral genome that is common to all strains of a virus, potentially eliminating the need for seasonal boosters

Improved vaccine includes Omicron variant’s spike protein and can offer enhanced protection in the 2023–2024 flu season 

Biopharmaceutical perspective on how the past, present, and future of mRNA technology will impact health care

2023 fall–winter is the first season when vaccines for all three major respiratory viruses are available

Nanoparticle vaccine targets six flu strains and may need to be taken less than once a year

First investigational flu vaccine may replace the seasonal flu shot and provide long-term immunity from various strains

The use of updated COVID-19 vaccines help protect against the more recent strains

Commencement of a Phase 1 clinical trial for a novel influenza vaccine

RSV causes severe disease burden among older adults and young children; there is no approved vaccine to prevent RSV

A new class of vaccines could prevent the next pandemic, though challenges remain